Please login to the form below

Not currently logged in

S-A collaboration with Harvard University

Sanofi-aventis will collaborate with Harvard University on translational biomedical research in several therapeutic areas, including cancer

Sanofi-aventis (S-A) will collaborate with Massachusetts-based Harvard University on translational biomedical research in several therapeutic areas, including cancer and diabetes.

The French pharmaceutical company will provide support and funding for research at the university, with an aim to advance knowledge in human health and promote scientific exchange between the two partners.

A Joint Scientific Steering Committee, made up of representatives from both Harvard and S-A, will select research projects to benefit from the partnership. The Committee will base decisions on the scientific merit of projects, as well as their potential to generate insight and value into biomedical research.

Dr Steven E Hyman, provost of Harvard University, said: "I'm delighted by the collaboration with sanofi-aventis, which joins together leaders in academic research and industry to more rapidly advance groundbreaking research from the lab to the clinic.

"This collaboration exemplifies Harvard's commitment to creatively partner with industry in ways that we hope will push the boundaries of translational science, and advance our mandate of serving the public interest by making the fruits of our research available to society."

During the collaboration, S-A will evaluate discoveries identified by Harvard's Office of Technology Development allowing the company the opportunity to develop relevant diagnostic, therapeutic and prognostic applications.

S-A will also host an annual scientific forum for university researchers to exhange knowledge on scientific matters, as well as to review the progress of relevant research projects.

Dr Marc Cluzel, executive vice-president, R&D, S-A, said: "We are hopeful that promoting open scientific exchange between Harvard's leading biological researchers and sanofi-aventis' drug development environment will drive significant healthcare advances. We are very excited about this collaboration."

As announced in September 2010, S-A already has a research collaboration with the Dana-Farber Cancer Institute - a principal teaching affiliate of Harvard Medical School. This partnership is to identify novel cancer targets for the development of new treatments.

19th October 2010


Featured jobs

Subscribe to our email news alerts


Add my company
Quintiles Medical Communications

Quintiles’ award-winning medical communications group sits at the heart of the enterprise. We offer a range of innovative strategic services,...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...